论文部分内容阅读
目的:探讨对小儿哮喘患儿采用孟鲁司特治疗的临床疗效。方法:收集84例小儿哮喘患儿作为研究对象,分为治疗组与对照组,均为42例,对照组给予布地奈德吸入治疗,治疗组在对照组的基础给予孟鲁司特片治疗。结果:治疗后,治疗组的总有效率为95.24%,明显高于对照组的76.19%,差异明显,具有统计学意义(P<0.05);治疗4周、8周后,治疗组的白天、夜间哮喘发作次数均明显优于对照组,差异明显,具有统计学意义(P<0.05);治疗组各项肺功能指标的改善程度均明显优于对照组,差异明显,具有统计学意义(P<0.05)。结论:对哮喘患儿采用孟鲁司特治疗,能有效改善患者的临床症状及肺功能,疗效显著。
Objective: To investigate the clinical efficacy of montelukast in children with asthma. Methods: Eighty-four pediatric asthmatic children were collected and divided into treatment group and control group, with 42 cases in each group. The control group was treated with inhalation of budesonide. The treatment group was given montelukast tablets on the basis of the control group. Results: After treatment, the total effective rate of the treatment group was 95.24%, which was significantly higher than that of the control group (76.19%), with significant difference (P <0.05). After treatment for 4 weeks and 8 weeks, The number of night asthma attacks were significantly better than the control group, the difference was statistically significant (P <0.05); the improvement of pulmonary function indicators in the treatment group were significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion: Montelukast treatment of children with asthma can effectively improve the clinical symptoms and pulmonary function in patients with significant effect.